Curing hepatitis C could yield huge economic benefit

(Digestive Disease Week) While a new generation of safer, more effective oral medications to treat hepatitis C patients may cost tens of thousands of dollars for a 12-week regiment, investing in these new therapies could generate savings estimated at more than $3.2 billion annually in the US and five European countries, according to a new study released today at Digestive Disease Week® 2015. These savings would have a significant economic impact on society.